Sunday, July 9, 2017
Saturday, July 8, 2017
Thursday, July 6, 2017
India Contract Research Organization Market, is projected to grow at a CAGR of 20.4% and is expected to reach US$ 6,310.5 million by 2022
A Contract Research Organization (CRO) is a service association that offers help to the pharmaceutical business and offers an extensive variety of outsourced pharmaceutical research administrations to help in R&D system and in this way a basic tool for undertaking clinical trials in the present situation when high stakes are included in the drug discovery process. This industry likewise offers a safe choice of venture as the business is to a great extent recession-proof, with a critical upscale development.
Wednesday, July 5, 2017
In August 2017, BIOCAD will receive permanent market authorization in India, which represents a strategic milestone for BIOCAD's international expansion.
Today, the Indian market for rituximab exceeds $40 m, with an annual growth of 8%. According to experts, this volume may reach $58 million in the next five years.
Meanwhile, India experiences low rituximab availability. Therefore, the Russian biosimilar marketed here will not only boost competition among the existing players, but will make this product available for larger numbers of patients with certain types of lymphomas and autoimmune disorders.
Sunday, June 25, 2017
With chikungunya spreading very fast in the country, researchers are seeking urgent government intervention for speedy completion of the vital clinical trials.
Chikungunya is a dreaded infection transmitted through the bite of the mosquito. There is no known cure and till date, there is no vaccine anywhere in the world again ..
The company says the phase-I trials will "evaluate the vaccine's safety, tolerability and immunogenicity. The placebo controlled study involving 60 healthy volunteers would test escalating doses of the vaccine in prime-boost regimen".
Sunday, June 18, 2017
Access to advanced research tools will expand growth opportunities for CRO participants, finds Frost & Sullivan's Transformational Health team
The clinical trials and research outsourcing (CRO) market is growing, leveraging the global pharmaceutical industry's urgent need to succeed in late clinical trials and build the pipeline of new molecules. While cost benefits, focus on core competencies, rise in innovative therapeutic options, and increased drug efficacy and safety norms will continue to encourage global pharma companies to outsource, CROs must increase their range of services to better serve, and become the preferred partner to, bio-pharmaceutical companies.
"Expanding CRO services into early stages of drugs, emergence of virtual biotech, out-licensing, and risk sharing between pharma and CROs are disrupting traditional business models," noted Transformational Health Research Analyst Sanjeev Kumar. "They are also opening up greater opportunities for CROs in terms of access to a huge market, newer areas such as commercial and post-launch, bioanalytical testing and development services, and partnerships with small-to-midsize biotech and virtual pharma customers."
Friday, June 16, 2017
"India Orthopedic Procedures Outlook to 2021", provides key procedures data on the India Orthopedic Procedures. The report provides procedure volumes within market categories - Hip Replacement Procedures, Knee Replacement Procedures, Shoulder Replacement Procedures, Small Joints Procedures, Arthroscopy Procedures, Cranio Maxillofacial Fixation (CMF) Procedures, Spinal Surgery Procedures, Trauma Fixation Procedures, Orthopedic Prosthetics (Amputation Procedures) and Orthobiologics Procedures (Bone Graft Procedures).
The data in the report is derived from dynamic market forecast models. uses epidemiology based models to estimate and forecast the procedure volumes. The objective is to provide information that represents the most up-to-date data of the industry possible.
The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.
Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the procedure volumes.
Thursday, June 15, 2017
Saturday, June 3, 2017
The drug `ofatumumab' for which the trial will start soon is expected to offer lesser side effects and will be more effective than the existing drug `teriflunomide' in patients who suffer from relapsing multiple sclerosis. In India, some 9-10 in every 1 lakh persons suffer from the disease. It is believed that there are over 1 lakh patients in the country .
Usually patients show recurring and recovering pattern of neurological symptoms (also called relapsing and remitting). The common symptoms include visual problems, overwhelming fatigue, difficulty in maintaining balance and coordination, various levels of impaired mobility , muscle weakness and stiffness.
Wednesday, May 17, 2017
Wednesday, March 1, 2017
Monday, February 27, 2017
Referring to episodes like overnight changes in key regulations governing clinical trials a few years back that destabilised investments of MNC pharma firms, Novartis global drug development head Vas Narasimhan said such inconsistencies send out wrong signals to investors.
Narasimhan, who was in India to participate in Bio Asia 2017 conclave at Hyderabad, said sudden regulatory shifts will affect MNC drug companies, who make long-term investments in innovation.
"We (multinationals) cannot simply keep adjusting. That sends a signal that maybe, we shouldn't invest as much," he told ET.
Admitting that things have improved in consistency with rest of the world and the regulatory environment has got better now from both intellectual property and clinical trials' perspective, he said, such environment enables MNCs "invest with certainty over longer periods of time."
However, he said "the key is it stays this way and keeps improving. Then, I think you will have more (clinical) trials coming in".
Novartis currently conducts more than 50 clinical trials in India across all its therapeutic segments.
Apart from ensuring consistency in regulatory policy environment, India should also allay the apprehensions of global investors at the earliest "so that it gives confidence to the principles all over the world because these clinical trials have been planned for long-term investments and they will have implications on global (drug) filings," Novartis India president Jawed Zia said.
Friday, February 24, 2017
Orbis Research Present's Chronic Pain-API Insights, 2017 And has been prepared based on an in-depth market analysis with inputs from industry experts.
Monday, February 20, 2017
Monday, January 9, 2017
Are poor still vulnerable?
And do the latest regulatory norms water down the safety norms?
With government waiving Phase III trials for drugs that are already tested in countries that have robust regulatory mechanism, does the pursuit of new drugs and vaccines have very few safeguards?